<DOC>
	<DOC>NCT00038506</DOC>
	<brief_summary>This study is a 48-week study to evaluate the efficacy and safety of an investigational regimen combining FDA approved HIV drugs in antiretroviral-experienced subjects failing on their first highly active antiretroviral therapy regimen.</brief_summary>
	<brief_title>Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
	<criteria>Currently on an initial HAART (highly active antiretroviral therapy) regimen of 3TC/ZDV or 3TC/d4T and a PI (protease inhibitor) boosted or unboosted or NNRTI (nonnucleoside reverse transcriptase inhibitor). Plasma HIV 1 RNA was &lt;400 copies/ml on at least 2 documented occasions prior to viral rebound. Have a plasma HIV 1 RNA value &gt;400 copies/ml and &lt;10,000 copies/ml on 2 documented successive occasions (including screen) separated by at least 2 weeks. A CD4+ lymphocyte count less than or equal to 100. Have not taken Abacavir (ZIAGEN or TRIZIVIR) or tenofovir (VIREAD) previously. Have not had an AIDS defining illness within 30 days of screen. Pregnant or breastfeeding. Specified viral genotypes upon screening. And other inclusion or exclusion criteria to be evaluated by the physician.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>HIV-1 TRIZIVIR Tenofovir</keyword>
</DOC>